Acute myeloid leukemia: advancing clinical trials and promising therapeutics

Naval Daver, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalReview article

Abstract

Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.

Original languageEnglish (US)
Pages (from-to)433-445
Number of pages13
JournalExpert Review of Hematology
Volume9
Issue number5
DOIs
StatePublished - May 3 2016
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Clinical Trials
Therapeutics
Signal Transduction
Leukemia
Antigens
Mutation
Antibodies

Keywords

  • AML
  • clinical trials
  • molecular therapy
  • monoclonal antibodies
  • multikinase inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

Acute myeloid leukemia : advancing clinical trials and promising therapeutics. / Daver, Naval; Cortes, Jorge; Kantarjian, Hagop; Ravandi, Farhad.

In: Expert Review of Hematology, Vol. 9, No. 5, 03.05.2016, p. 433-445.

Research output: Contribution to journalReview article

Daver, Naval ; Cortes, Jorge ; Kantarjian, Hagop ; Ravandi, Farhad. / Acute myeloid leukemia : advancing clinical trials and promising therapeutics. In: Expert Review of Hematology. 2016 ; Vol. 9, No. 5. pp. 433-445.
@article{a33ef4cb5d134456bc38c14f605c09ec,
title = "Acute myeloid leukemia: advancing clinical trials and promising therapeutics",
abstract = "Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.",
keywords = "AML, clinical trials, molecular therapy, monoclonal antibodies, multikinase inhibitors",
author = "Naval Daver and Jorge Cortes and Hagop Kantarjian and Farhad Ravandi",
year = "2016",
month = "5",
day = "3",
doi = "10.1586/17474086.2016.1158096",
language = "English (US)",
volume = "9",
pages = "433--445",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Acute myeloid leukemia

T2 - advancing clinical trials and promising therapeutics

AU - Daver, Naval

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.

AB - Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.

KW - AML

KW - clinical trials

KW - molecular therapy

KW - monoclonal antibodies

KW - multikinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84961198329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961198329&partnerID=8YFLogxK

U2 - 10.1586/17474086.2016.1158096

DO - 10.1586/17474086.2016.1158096

M3 - Review article

C2 - 26910051

AN - SCOPUS:84961198329

VL - 9

SP - 433

EP - 445

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 5

ER -